Sintilimab Clinical Trials

7 recruiting

Sintilimab Trials at a Glance

7 actively recruiting trials for sintilimab are listed on ClinicalTrialsFinder across 5 cities. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Hangzhou, and Changsha. Lead sponsors running sintilimab studies include Sun Yat-sen University, Zhejiang Cancer Hospital, and Anhui Provincial Cancer Hospital.

Browse sintilimab trials by phase

Treatments under study

About Sintilimab Clinical Trials

Looking for clinical trials for Sintilimab? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sintilimab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sintilimab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

NSCLCSintilimabAdaptive Radiotherapy
The Third Xiangya Hospital of Central South University35 enrolled1 locationNCT07138755
Recruiting
Phase 2

Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

SintilimabCentral Nervous System LymphomaPirtobrutinib
Zhejiang Cancer Hospital24 enrolled1 locationNCT07416890
Recruiting
Phase 2

Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma

Hepatocellular CarcinomaNeoadjuvant TherapySintilimab+1 more
Sun Yat-sen University37 enrolled1 locationNCT07324824
Recruiting
Phase 2

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

NSCLCLow Dose RadiotherapyNeoadjuvant Immunotherapy+1 more
Anhui Provincial Cancer Hospital86 enrolled1 locationNCT06714708
Recruiting
Not Applicable

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Hepatocellular CarcinomaImmunotherapySintilimab+2 more
Sun Yat-sen University30 enrolled1 locationNCT06070636
Recruiting
Phase 2

Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma

Esophageal CancerImmunotherapyChemoradiotherapy+2 more
Zhejiang Cancer Hospital191 enrolled1 locationNCT06413342
Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal CarcinomaSintilimab
Cancer Hospital of Guangxi Medical University43 enrolled1 locationNCT05707819